AI Insight
New data have prompted health-evidence reviewers to reverse their long-standing recommendation regarding the PSA (prostate-specific antigen) blood test used to screen for prostate cancer. After decades of controversy over whether the test reduces mortality or leads primarily to overdiagnosis and overtreatment, updated evidence suggests the test may offer a measurable survival benefit. This reversal marks a significant shift from the previous gold-standard position that had discouraged routine PSA screening in many clinical guidelines.
Why it matters
This change in recommendation could directly influence clinical practice and public health policy worldwide, potentially expanding access to or endorsement of PSA screening for men at risk of prostate cancer. It may also affect how physicians counsel patients about the balance between early detection benefits and the risks of unnecessary intervention.
Nature, Published online: 14 May 2026; doi:10.1038/d41586-026-01549-x
Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of controversy.
Source: Does the PSA test for prostate cancer save lives? New data reverse gold-standard findings